logo

GRANULES vs MARKSANS: Stock Comparison

GRANULES INDIA vs MARKSANS PHARMAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. GRANULES INDIA shows faster revenue growth, while MARKSANS PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GRANULES leads 3; MARKSANS leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GRANULESMARKSANS

Valuation lens

What price are you paying?

Market CapContext only
₹22,358 Cr
₹13,595 Cr
P/E RatioMARKSANS has the lower reading
30.39x
26.32x ✓
P/B RatioGRANULES has the lower reading
3.99x ✓
4.5x
EPSGRANULES has the higher reading
₹7.26 ✓
₹3.47
Book ValueContext only
₹205.21
₹67.36
Dividend YieldMARKSANS has the higher reading
0.22%
0.3% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹22,358 Cr vs ₹13,595 Cr
P/E Ratio
MARKSANS has a lower P/E
26.32x vs 30.39x
P/B Ratio
GRANULES has a lower P/B
3.99x vs 4.5x
EPS
GRANULES has higher earnings per share
₹7.26 vs ₹3.47
Dividend Yield
MARKSANS has a higher dividend yield
0.3% vs 0.22%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 20.8%
EPS Growth (TTM YoY)
MARKSANS has faster EPS growth
63.5% vs 31.3%
ROE
MARKSANS has a higher ROE
18.2% vs 9.11%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESMARKSANS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESMARKSANS
Live Price₹817₹294.45
Day Change1.16%-1.24%
Volume5.12 L8.18 L
52-Week High₹923.65₹350.95
52-Week Low₹529.85₹155
Distance from 52W High-11.55%-16.1%

Valuation

MetricGRANULESMARKSANS
Market Cap₹22,358 Cr₹13,595 Cr
P/E Ratio30.39x26.32x
P/B Ratio3.99x4.5x
EPS₹7.26₹3.47
Book Value₹205.21₹67.36
Dividend Yield0.22%0.3%

Growth

MetricGRANULESMARKSANS
Revenue Growth (TTM YoY)22.8%20.8%
EPS Growth (TTM YoY)31.3%63.5%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricGRANULESMARKSANS
ROE9.11%18.2%
ROCE9.07%19.33%
Net Margin11.15%14.16%
Operating Margin17.19%29.29%
Debt to Equity0.17x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricGRANULESMARKSANS
Promoter Holding37.08%▼ 0.59 pp43.87%
FII Holding20.25%▲ 2.75 pp19.06%▲ 1.59 pp
DII Holding15.33%▼ 0.78 pp5.54%▼ 0.65 pp
Public Holding27.04%▼ 1.34 pp31.53%▼ 0.94 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRANULES INDIA and MARKSANS PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.